IGMPI Approvals & Accreditation : Approved by Quality Council of India (QCI) & Accredited Vocational Institution of Ministry of HRD, Government of India, Approved Training Institute of Food Safety and Standards Authority of India (FSSAI), Recognized by Department of Industrial Policy & Promotion, Ministry of Commerce & Industry, Government of India, An ISO 9001:2015 Certified Organisation registered under The Societies Registration Act,1860 Government of India Empanelled under Ministry of Horticulture and Food Processing, Government of Uttar Pradesh, Affiliated with Life Sciences and Food Industry Sector Skills Council (SSC)
Trusted by organizations & training participants in over 30 countries. Training | Certification | Education | Research

Genentech’s Phase III trial successful for comparable efficacy between Xofluza and Tamiflu

03rd July 2019

Reports emerged that Genentech, a Roche company reached primary endpoint of its Phase III clinical trial called MINISTONE-2, demonstrating that Xofluza (balaxavir marboxil) was comparable to Tamiflu (oseltamivir). Tamiflu has been prevalent in the market from last two decades. Xofluza is broadly approved in the markets of Japan for people older than 12 years. The objective of the company behind this trial is to market Xofluza as an alternative to Tamiflu.

Clinical trial was conducted on children between the ages of one to twelve, who were suffering from Flu infection. Confirmatory tests; rapid influenza test were done to include the subject as per inclusion criteria. Outcome of the test showed symptoms similar to influenza which includes 38°C or higher temperature along with one or more respiratory symptoms.

Study was divided into two cohorts. Cohort one included subjects (children) from one year to five years while Cohort two included subjects from five years to twelve years. Subjects had randomly received one dose (adjusted as per the BMI) of Xofluza or Tamiflu twice a day over five days.

Genentech has announced that the trial has met the primary endpoints, which shows that the Xofluza is well tolerated among children in comparison to Tamiflu administered for the reduction in symptoms and duration of Flu.

For further enquiries, write to or call us on:
info@igmpiindia.org/ +91 8587838177, +91 8130924488, 0120-2427175, 0120-4375280

Pharmaceuticals | Food | Clinical Research | Healthcare | Medical Coding | Medical Device | Nanotechnology | IPR

Clinical Research Newsletter

Featured Article

GMP: A continous process

Mr Vinod Arora, Principal Advisor, IGMPI

IGMPI Placement Blog

Placement Testimonials

Placement testimonials: Our alumni are working with Fortune 500 and global Pharmaceutical, Food and healthcare giants like